

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
25 August 2022 (25.08.2022)



(10) International Publication Number
WO 2022/175414 A1

(51) International Patent Classification:

A61P 35/00 (2006.01) C07K 16/30 (2006.01)
A61K 35/17 (2015.01) C07K 16/32 (2006.01)
C07K 16/28 (2006.01) C07K 16/40 (2006.01)
C12N 5/0783 (2010.01)

(21) International Application Number:

PCT/EP2022/054011

(22) International Filing Date:

17 February 2022 (17.02.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2102224.9 17 February 2021 (17.02.2021) GB
2111685.0 14 August 2021 (14.08.2021) GB

(71) Applicants: **ADAPTATE BIOTHERAPEUTICS LTD.** [GB/GB]; WestWorks, 195 Wood Lane, White City Place, London W12 7FQ (GB). **F-STAR THERAPEUTICS LIMITED** [GB/GB]; Eddeva B920, Babraham Research Campus, Cambridge, Cambridgeshire, CB22 3AT (GB).

(72) Inventors: **TUNA, Mihriban**; c/o Adaptate Biotherapeutics Ltd., WestWorks, 195 Wood Lane, White City Place, London W12 7FQ (GB). **UDEN, Mark**; c/o Adaptate Biotherapeutics Ltd., WestWorks, 195 Wood Lane, White City Place, London W12 7FQ (GB). **FREEDMAN, Joshua**; c/o Adaptate Biotherapeutics Ltd., WestWorks, 195 Wood Lane, White City Place, London W12 7FQ (GB). **MOUNT, Natalie**; c/o Adaptate Biotherapeutics Ltd., WestWorks, 195 Wood Lane, White City Place, London W12 7FQ (GB).

(74) Agent: **HEATH, Abigail**; Kilburn & Strode LLP, Lacon London, 84 Theobalds Road, London WC1X 8NL (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: MULTISPECIFIC ANTI-TCR DELTA VARIABLE I ANTIBODIES

(57) Abstract: The present invention provides multispecific antibodies comprising a Fab region and an Fc region, wherein the Fab region comprises a binding site specific for an epitope of the variable delta 1 (Vδ1) chain of a γδ T cell receptor (TCR); and the Fc region comprises an EGFR binding site. The present invention also provides compositions and pharmaceutical compositions comprising such multispecific antibodies, and method of making such multispecific antibodies. The present invention also provides methods of treatment and medical uses involving the multispecific antibodies.

WO 2022/175414 A1